Can the use of smokeless tobacco products be Accepted as a harm reduction method in tobacco Addiction?

AKÇAY, MÜŞERREF ŞULE; KÜÇÜK UYANUSTA, Çağla; AYTEMUR, ZEYNEP AYFER; KILINC, OGUZ; DAĞLI, Elif; Elbek, Osman; Öztuna, Funda

Can the use of smokeless tobacco products be Accepted as a harm reduction method in tobacco Addiction?

Funda ÖZTUNA, (Karadeniz Teknik Üniversitesi, Tıp Fakültesi, Göğüs Hastalıkları, İç Hastalıkları, Anabilim Dalı, Trabzon, Türkiye)

Zeynep Ayfer AYTEMUR, (İnönü Üniversitesi, Tıp Fakültesi, Göğüs Hastalıkları Anabilim Dalı, Malatya, Türkiye)

Osman ELBEK, (Aydın Üniversitesi, Tıp Fakültesi, Göğüs Hastalıkları, İç Hastalıkları Anabilim Dalı, Aydın, Türkiye)

Oğuz KILINÇ, (Dokuz Eylül Üniversitesi, Tıp Fakültesi, Göğüs Hastalıkları, İç Hastalıkları Anabilim Dalı, İzmir, Türkiye)

Çağla KÜÇÜK UYANUSTA, (Dışkapı Yıldırım Beyazıt Eğitim ve Araştırma Hastanesi, Göğüs Hastalıkları Kliniği, Ankara, Türkiye)

MÜŞERREF ŞULE AKÇAY, (Başkent Üniversitesi, Tıp Fakültesi, Göğüs Hastalıkları ve İç Hastalıkları Anabilim Dalı, Ankara, Türkiye)

Elif DAĞLI (Marmara Üniversitesi, Tıp Fakültesi, İstanbul, Türkiye)

Türk Toraks Dergisi

0 0

Yıl: 2014 Cilt: 15 Sayı: 4 Sayfa Aralığı: 136 - 141 Metin Dili: İngilizce İndeks Tarihi: 29-07-2022

Can the use of smokeless tobacco products be Accepted as a harm reduction method in tobacco Addiction?

Öz:

The goal of smoking cessation treatment is to keep the patient completely away from tobacco and tobacco products. The aim of harmreduction strategies in tobacco control is to reduce the risks associated with tobacco use. In order to turn it into an opportunity, tobaccocompanies have developed smokeless tobacco products. Some epidemiological studies have reported that smokeless tobacco productsare safer than tobacco smoke. However, this method is not completely harmless. In this review, we will discuss all aspects of tobaccoharm reduction methods.

Anahtar Kelime:

Konular: Solunum Sistemi Kulak, Burun, Boğaz

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Rodu B. The scientifc foundation for tobacco harm reduction, 2006-2011. Harm Reduct J 2011;29:19. [ CrossRef]
2. Boffetta P, Hecht S, Gray N, et al. Smokeless tobacco and can - cer. Lancet Oncol 2008;9:667-75. [ CrossRef]
3. Lee PN, Hamling J. Systematic review of the relation between smokeless tobacco and cancer in Europe and North America. BMC Medicine 2009;7:36. [CrossRef]
4. Lee PN. Circulatory disease and smokeless tobacco in West- ern populations: a review of the evidence. Int J Epidemiol 2007;36:789-804. [CrossRef]
5. Boffetta P, Straif K. Use of smokeless tobacco and risk of myo - cardial infarction and stroke: systematic review with meta-anal - ysis. BMJ 2009;18:b3060. [CrossRef]
6. England LJ, Levine RJ, Mills JL, et al. Adverse pregnancy outcomes in snuff users. Am J Obstet Gynecol 2003;189:939-43. [ CrossRef]
7. Ramström LM, Foulds J. Role of snus in initiation and cessation of to - bacco smoking in Sweden. Tob Control 2006;15:210-4. [CrossRef]
8. Lund KE, McNeill A, Scheffels J. The use of snus for quitting smoking compared with medicinal products. Nicotine Tob Res 2010;12:817-22. [CrossRef]
9. Rodu B, Godshall WT. Tobacco harm reduction: an alternative cessation strategy for inveterate smokers. Harm Reduction Jour- nal 2006;37:1-23.
10. Rodu B, Cole P. Evidence against a gateway from smokeless tobac - co use to smoking. Nicotine Tob Res 2010;12:530-4. [ CrossRef]
11. Frost-Pineda K, Appleton S, Fisher M, Fox K, Gaworski CL. Does dual use jeopardize the potential role of smokeless tobacco in harm reduction? Nicotine Tob Res 2010;12:1055-67. [CrossRef]
12. Euromonitor International. Global briefng- Global tobacco fndings 2011: Battle intensifes. Euromonitor International; 2011:56.
13. Ayo-Yusuf OA, Burns DM. The complexity of harm reduc - tion with smokeless tobacco as an approach to tobacco con - trol in low-income and middle-income countries. Tob Control 2012;21:245-51. [CrossRef]
14. Bialous SA, Peeters S. The shameful pastA brief overview of the tobac - co industry in the last 20 years. Tob Control 2012;21:92-4. [CrossRef]
15. Global Tobacco-Key Findings Part Two-Other Tobacco Products Overview and Competitive Environment 2010:27.
16. Gilmore AB. Tobacco epidemic today. Understanding the vector in order to plan effective tobacco control policies: an analy - sis of contemporary tobacco industry materials. Tob Control 2012;21:119-26. [CrossRef]
17. OReilly D. Harm reduction. BAT Investor Day, 17-18 May 2011. Hampshire, 2011.
18. Stratton K, Shetty P, Wallace R, Bondurant S, (eds): Clearing the smoke. Assessing the science base for tobacco harm reduction. Insti- tute of Medicine. National Academy Press, Washington, DC; 2001.
19. Russell MAH. Realistic goals for smoking and health: a case forsafer smoking. Lancet 1974;1:254-8. [ CrossRef]
20. Russell MAH, Jarvis MJ, Feyerabend C. A new age for snuff? Lancet 1980;1:474-5. [CrossRef] 21. Kirkland LR. The nonsmoking uses of tobacco. New Engl J Med 1980;303:165. [ CrossRef]
22. Russell MAH, Jarvis MJ, Devitt G, Feyerabend C. Nicotine in - take by snuff users. BMJ 1981;283:814-7. [ CrossRef]
23. Russell MAH, Jarvis MJ, West RJ, Feyerabend C. Buccal ab - sorption of nicotine from smokeless tobacco sachets. Lancet 1985;2:1370. [ CrossRef]
24. Paul Koening. Method for cultivating tobacco-Patent no:1997369. www.LitmanLaw.com/FreeInformation. 25. Patent Searching and Inventing Resources. www.freepatentson - line.com.
26. Hoffmann D, Hoffmann I. The changing cigarette, 1950-1995. J Toxicol Environ Health 1997;50:307-64. [CrossRef]
27. Wayne GF. Potential reduced exposure products (PREPs) in in - dustry trial. Tobacco Control 2006;15(Suppl 4):90-7. [ CrossRef]
28. US Department of Health and Human Services. Smoking and Tobacco Control Monograph 13: risks associated with smok - ing cigarettes with low tar machine-measured yields of tar and nicotine, US Department of Health and Human Services. Public Health Service. National Institutes of Health. National Cancer Institute, October, 2001.
29. Thun MJ, Burns DM. Health impact of reduced yield cigarettes: a critical assessment of the epidemiological evidence. Tob Con - trol 2001;10(Supp 2):4-11.
30. Pollay RW, Dewhirst T. The dark side of marketing seemingly Lightcigarettes: successful images and failed fact. Tob Control 2002;11(Suppl 1):18-31. [CrossRef]
31. Ahlbom A, Olsson UA, Pershagen G. Health risks associated with moist snuff. Socialstyrelsen (Swedish National Board of Health and Welfare), Stockholm, Sweden 1997.
32. Centers for Disease Control and Prevention, 1993: Use of Smokeless Tobacco Among Adults United States. MMWR 1991;42:263-6.
33. Tomar SL. Trends and patterns of tobacco use in the United States. Am J Med Sci 2003;326:248-54. [ CrossRef]
34. Tobacco use compared to other drug dependencies. In The Health Consequences of Smoking: Nicotine Addiction. A Re - port of the Surgeon General Volume Chapter V. U.S. Depart- ment of Health and Human Services, Centers for Disease Con - trol, Rockville, MD; 1988.
35. American Cancer Society: Spit (Smokeless) Tobacco. [http:// www.cancer.org/docroot/PED/content/PED-10-2x-Smokeless- Tobacco-and-Cancer.asp?sitearea=PED]
36. Savitz DA, Meyer RE, Tanzer JM, et al. Public health ımplications of smokeless tobacco use as a harm reduction strategy. Am J Public Health 2006;96:1934-9. [ CrossRef]
37. Hoffmann D, Adams JD, Lisk D, et al. Toxic and carcinogenic agents in dry and moist snuff. J Natl Cancer Inst 1987;79:1281-6.
38. Boyle P, Macfarlane GJ, Maisonneuve P, et al. Epidemiology of mouth cancer in 1989: a review. J R Soc Med 1990;83:724-30.
39. McLaughlin JK, Gridley G, Block G, et al. Dietary factors in oral and pharyngeal cancer. J Natl Cancer Inst 1988;80:1237-43. [CrossRef]
40. Scully C. Oncogenes, tumor suppressors and viruses in oral squamous cell carcinoma. J Oral Pathol Med 1993;22:337-47. [ CrossRef]
41. Westman EC. Does smokeless tobacco cause hypertension? South Med J 1995;88:716-20. [ CrossRef]
42. Edwards JG. An unusual case of nicotine dependence. Psychol Med 1987;17:779-81. [ CrossRef]
43. Tucker LA. Use of smokeless tobacco, cigarette smoking, and hyper- cholesterolemia. Am J Public Health 1989;79:1048-50. [CrossRef]
44. Huhtasaari F, Asplund K, Lundberg V, et al. Tobacco and myo - cardial infarction: is snuff less dangerousthan cigarettes? BMJ 1992;305:1252-6. [CrossRef]
45. Huhtasaari F, Lundberg V, Eliasson M, et al. Smokeless tobac - co as a possible risk factor for myocardial infarction. A pop - ulation-based study in middle-aged men. J Am Coll Cardiol 1999;34:1784-90. [ CrossRef]
46. Accortt NA, Waterbor JW, Beall C, Howard G. Chronic disease mortality in a cohort of smokeless tobacco users. Am J Epide- miol 2002;156:730-7. [ CrossRef]
47. Hergens M, Ahlbom A, Andersson T, Pershagen G. Swedish moist snuff and myocardial infarction among men. Epidemiol 2005;16:12-6. [CrossRef]
48. Johansson S, Sundquist K, Qvist J, Sundquist J. Smokeless to - bacco and coronary heart disease: a 12-year follow-up study. J Cardiovasc Prevent Rehab 2005;12:387-92. [ CrossRef]
49. Henley SJ, Thun MJ, Connell C, Calle EE. Two large prospective studies of mortality among men who use snuff or chewing tobacco (United States). Cancer Cause Contr 2005;16:347-58. [ CrossRef]
50. Bolinder G, Alfredsson L, Englund A, de Faire U. Smokeless tobacco use and increased cardiovascular mortality amongSwedish con- struction workers. Am J Pub Health 1995;84:399-404. [ CrossRef]
51. Asplund K, Nasic S, Janlert U, Stegmayr B. Smokeless tobacco as a possible risk factor for stroke in men: a nested case-control study. Stroke 2003;34:1754-9. [CrossRef]
52. Feskens EJ, Kromhout D. Cardiovascular risk factors and the 25- year incidence of diabetes mellitus in middle-aged men. The Zutphen Study. Am J Epidemiol 1989;130:1101-8.
53. Rimm EB, Manson JE, Stampfer MJ, et al. Cigarette smoking and the risk of diabetes in women. Am J Public Health 1993;83:211-4. [CrossRef]
54. Perry IJ, Wannamethee SG, Walker MK, et al. Prospective study of risk factors for development of noninsulin dependent diabetes in middle aged British men. Br Med J 1995;310:560- 4. [CrossRef]
55. Rimm EB, Chan J, Stampfer MJ, et al. Prospective study of ciga - rette smoking, alcohol use, and the risk of diabetes in men. Br Med J 1995;310:555-9. [ CrossRef]
56. Persson PG, Carlsson S, Svanstrom L, et al. Cigarette smok- ing, oral moist snuff use and glucose intolerance. J Intern Med 2000;248:103-10. [ CrossRef]
57. Greer RO, Poulson TC, Boone ME, et al. Smokeless tobacco associated oral changes in juvenile, adult and geriatic pa - tients: Clinical and histomorphologic features. Gerodontics 1986;2:87-98.
58. Andersson G, Axell T. Clinical appearance of lesions associated with the use of loose and portion-bag packed Swedish moist snuff: a comparative study. J Oral Pathol Med 1989;18:2-7. [ CrossRef]
59. Smith JF, Mincer HA, Hopkins KP, Bell J. Snuff-dippers lesion. A cytological and pathological study in a large population. Arch Otolarynngol 1970;92:450-6. [ CrossRef]
60. Roed-Petersen B, Pindborg JJ. A study of snuff induced oral leu - koplakias. J Oral Pathol 1973;2:301-3. [ CrossRef]
61. Axell T, Mornstad H, Sundstrom B. The relation of the clinical picture to the histopathology of snuff dippers lesions in a Swed - ish population. J Oral Pathol 1976;5:229-36. [CrossRef]
62. Axell T, Mornstad H, Sundstrom B. Snuff and cancer of the oral cavity. A retrospective study. Läkartidningen 1978;75:1224-6.
63. Rodu B, Cole P. Smokeless tobacco use and cancer of the upper respiratory tract. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2002;93:511-5. [ CrossRef]
64. Schildt EB, Eriksson M, Hardell L, Magnuson A. Oral snuff, smoking habits and alcohol consumption in relation to oral cancer in a Swed- ish case-control study. Int J Cancer 1998;77:341-6. [CrossRef]
65. Lewin F, Norell SE, Johansson H, et al. Smoking tobacco, oral snuff, and alcohol in the etiology of squamous cell carcinoma of the head and neck: a population-based case-referent study in Sweden. Cancer 1998;82:1367-75. [CrossRef]
66. European Commission: Directive 2001/37/EC of the European Parliament and of the Council.[http://europa.eu.int/eurlex/pri/ en/oj/dat/2001/l_194/l_19420010718en00260034.pdf]. June 5, 2001.
67. Hecht SS, Rivenson A, Braley J, et al. Induction of oral cavity tu - mors in F344 rats by tobacco-specif c. nitrosamines and snuff. Cancer Res 1986;46:4162-6.
68. Rivenson A, Hoffmann D, Prokopczyk B, et al. Induction of lung and exocrine pancreas tumors in F344 rats by tobacco-specif c and Areca-derived N-nitrosamines. Cancer Res 1988;48:6912-7.
69. Hecht SS. Biochemistry, biology, and carcinogenicity of tobac - cospecif c N-nitrosamines. Chem Res Toxicol 1998;11:559- 603. [ CrossRef]
70. Waterbor J, Adams R, Robinson J, et al. Disparities between public health educational material and the scientifc evidence that smokeless tobacco use causes cancer. J Cancer Educ 2004;19:17-28. [ CrossRef]
71. Zendehdel K, Nyrén O, Luo J, et al. Risk of gastroesophageal cancer among smokers and users of Scandinavian moist snuff. Int J Cancer 2008;122:1095-9. [ CrossRef]
72. Luo J, Ye W, Zendehdel K, et al. Oral use of Swedish moist snuff (snus) and risk for cancer of the mouth, lung, and pancreas in male construction workers: a retrospective cohort study. Lancet 2007;16:2015-20. [ CrossRef]
73. Slotkin TA. Fetal nicotine or cocaine exposure: which one is worse? J Pharmacol Exp Ther 1998;285:931-45.
74. Carmines EL, Rajendran N. Evidence for carbon monoxide as the major factor contributing to lower fetal weights in rats exposed to cigarette smoke. Toxicol Sci 2008;102:383-91. [CrossRef]
75. Paulson RB, Shanfeld J, Prause L, et al. Pre-and post-conception - al tobacco effects on the CD-1 mouse fetus. J Craniofac Genet Dev Biol 1991;11:48-58.
76. Paulson RB, Shanfeld J, Mullet D, et al. Prenatal smokeless tobacco effects on the rat fetus. J Craniofac Genet Dev Biol 1994;14:16-25.
77. Benowitz NL, Porchet H, Sheiner L, Jacob P. Nicotine absorp - tion and cardiovascular effects with smokeless tobacco use: comparison with cigarettes and nicotine gum. Clin Pharmacol Ther 1988;44:23-8. [CrossRef]
78. Fant RV, Henningfeld JE, Nelson RA, Pickworth WB. Pharmaco - kinetics and pharmacodynamics of moist snuff in humans. Tob Control 1999;8:387-92. [CrossRef]
79. England LJ, Levine RJ, Qian C, et al. Smoking before pregnancy and risk of gestational hypertension and preeclampsia. Am J Obstet Gynecol 2002;186:1035-40. [ CrossRef]

APA	Öztuna F, AYTEMUR Z, Elbek O, KILINC O, KÜÇÜK UYANUSTA Ç, AKÇAY M, DAĞLI E (2014). Can the use of smokeless tobacco products be Accepted as a harm reduction method in tobacco Addiction?. , 136 - 141.
Chicago	Öztuna Funda,AYTEMUR ZEYNEP AYFER,Elbek Osman,KILINC OGUZ,KÜÇÜK UYANUSTA Çağla,AKÇAY MÜŞERREF ŞULE,DAĞLI Elif Can the use of smokeless tobacco products be Accepted as a harm reduction method in tobacco Addiction?. (2014): 136 - 141.
MLA	Öztuna Funda,AYTEMUR ZEYNEP AYFER,Elbek Osman,KILINC OGUZ,KÜÇÜK UYANUSTA Çağla,AKÇAY MÜŞERREF ŞULE,DAĞLI Elif Can the use of smokeless tobacco products be Accepted as a harm reduction method in tobacco Addiction?. , 2014, ss.136 - 141.
AMA	Öztuna F,AYTEMUR Z,Elbek O,KILINC O,KÜÇÜK UYANUSTA Ç,AKÇAY M,DAĞLI E Can the use of smokeless tobacco products be Accepted as a harm reduction method in tobacco Addiction?. . 2014; 136 - 141.
Vancouver	Öztuna F,AYTEMUR Z,Elbek O,KILINC O,KÜÇÜK UYANUSTA Ç,AKÇAY M,DAĞLI E Can the use of smokeless tobacco products be Accepted as a harm reduction method in tobacco Addiction?. . 2014; 136 - 141.
IEEE	Öztuna F,AYTEMUR Z,Elbek O,KILINC O,KÜÇÜK UYANUSTA Ç,AKÇAY M,DAĞLI E "Can the use of smokeless tobacco products be Accepted as a harm reduction method in tobacco Addiction?." , ss.136 - 141, 2014.
ISNAD	Öztuna, Funda vd. "Can the use of smokeless tobacco products be Accepted as a harm reduction method in tobacco Addiction?". (2014), 136-141.

APA	Öztuna F, AYTEMUR Z, Elbek O, KILINC O, KÜÇÜK UYANUSTA Ç, AKÇAY M, DAĞLI E (2014). Can the use of smokeless tobacco products be Accepted as a harm reduction method in tobacco Addiction?. Türk Toraks Dergisi, 15(4), 136 - 141.
Chicago	Öztuna Funda,AYTEMUR ZEYNEP AYFER,Elbek Osman,KILINC OGUZ,KÜÇÜK UYANUSTA Çağla,AKÇAY MÜŞERREF ŞULE,DAĞLI Elif Can the use of smokeless tobacco products be Accepted as a harm reduction method in tobacco Addiction?. Türk Toraks Dergisi 15, no.4 (2014): 136 - 141.
MLA	Öztuna Funda,AYTEMUR ZEYNEP AYFER,Elbek Osman,KILINC OGUZ,KÜÇÜK UYANUSTA Çağla,AKÇAY MÜŞERREF ŞULE,DAĞLI Elif Can the use of smokeless tobacco products be Accepted as a harm reduction method in tobacco Addiction?. Türk Toraks Dergisi, vol.15, no.4, 2014, ss.136 - 141.
AMA	Öztuna F,AYTEMUR Z,Elbek O,KILINC O,KÜÇÜK UYANUSTA Ç,AKÇAY M,DAĞLI E Can the use of smokeless tobacco products be Accepted as a harm reduction method in tobacco Addiction?. Türk Toraks Dergisi. 2014; 15(4): 136 - 141.
Vancouver	Öztuna F,AYTEMUR Z,Elbek O,KILINC O,KÜÇÜK UYANUSTA Ç,AKÇAY M,DAĞLI E Can the use of smokeless tobacco products be Accepted as a harm reduction method in tobacco Addiction?. Türk Toraks Dergisi. 2014; 15(4): 136 - 141.
IEEE	Öztuna F,AYTEMUR Z,Elbek O,KILINC O,KÜÇÜK UYANUSTA Ç,AKÇAY M,DAĞLI E "Can the use of smokeless tobacco products be Accepted as a harm reduction method in tobacco Addiction?." Türk Toraks Dergisi, 15, ss.136 - 141, 2014.
ISNAD	Öztuna, Funda vd. "Can the use of smokeless tobacco products be Accepted as a harm reduction method in tobacco Addiction?". Türk Toraks Dergisi 15/4 (2014), 136-141.